Get the Stockscreener App
0.00
100.00%
-9.02
Range Cancer Therapeutics Etf stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$9.02
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$16.27
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
Name
Range Cancer Therapeutics Etf
Sector
Industry
Phone
-
Address
-
Compare CNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
299.36 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
607.12 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
609.96 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
233.78 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
541.16 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf Stock (CNCR) Latest News
Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail
(CNCR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor - Yahoo Finance
Summit stock down after cancer trial data (update) (NASDAQ:SMMT) - Seeking Alpha
Friday's big stock stories: What’s likely to move the market in the next trading session - CNBC
5 Small-cap Biotech ETFs to Watch - Investing News Network
Trend Tracker for (CNCR) - news.stocktradersdaily.com
CIBC Asset Management launches three new actively managed CIBC ETFs, expanding its cash management and fixed income ETF suite - The Globe and Mail
Weekly ETF Industry Recap: U.S., Europe, and Canada HighlightsMay 5-10, 2025 - Trackinsight
Exchange Traded Concepts to Close and Liquidate the Range Cancer Therapeutics ETF - The Joplin Globe
Learn to Evaluate (CNCR) using the Charts - news.stocktradersdaily.com
Cold Spring Harbor Laboratory’s Ludmila Pollock lauded as fellow of AAAS - TBR News Media
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Cathie Wood Bets on Nvidia, AMD Despite Chip Curbs and Dumps Microsoft Stock - The Globe and Mail
Long Term Trading Analysis for (CNCR) - news.stocktradersdaily.com
7 Best Pharmaceutical Stocks to Buy for Income | Investing - US News Money
From Panic to Positioning: Top ETFs to Watch After Asia’s Tariff Shock - The Globe and Mail
(CNCR) Investment Report - news.stocktradersdaily.com
10 Best Health Care Stocks to Buy for 2025 - US News Money
7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News
Best Stocks Under $20 Right Now - Benzinga
Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - Nasdaq
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Nasdaq
QQQ ETF News, 3/19/2025 - The Globe and Mail
(CNCR) Proactive Strategies - Stock Traders Daily
Nasdaq Correction: Buy This Unstoppable ETF at a Discount - The Globe and Mail
Buffer ETFs to Consider for Protecting Gains and Limiting Losses - The Globe and Mail
S&P 500 Index Funds Yield Just 1.3%. Consider Buying These 2 Low-Cost Vanguard ETFs to Generate More Passive Income. - The Globe and Mail
VOO ETF News, 3/14/2025 - The Globe and Mail
Bull or Bear, These 2 ETFs Don’t Care - The Globe and Mail
VOO ETF News, 3/12/2025 - The Globe and Mail
Is the Fidelity High Dividend ETF the Smartest Investment You Can Make Today? - The Globe and Mail
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You? - The Globe and Mail
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? - The Globe and Mail
SCHD ETF News, 3/11/2025 - The Globe and Mail
1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Globe and Mail
Why You Can Do Better Than the SPDR S&P 500 ETF Trust - The Globe and Mail
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Best Biotech Stocks to Buy in 2025 - The Motley Fool
(CNCR) Investment Analysis - news.stocktradersdaily.com
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Top ETFs to Invest in Japan - The Globe and Mail
N2OFF, Inc. Enters Agreement to Acquire MitoCareX Bio Ltd. to Expand Cancer Therapeutics Portfolio - Nasdaq
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025 - Investing News Network
CIBC Asset Management announces CIBC ETF cash distributions for February 2025 - The Globe and Mail
(CNCR) Trading Signals - Stock Traders Daily
The Unstoppable Momentum in Oncology M&A - Nasdaq
2025 Outlook: Healthcare Technology & Innovation - ETF Trends
This Warren Buffett Index Fund Could Turn $400 Per Month Into $868,200 - The Globe and Mail
Psychedelic ETF PSIL Is 2025's Best-Performing ETF - etf.com
Range Cancer Therapeutics Etf Stock (CNCR) Financials Data
There is no financial data for Range Cancer Therapeutics Etf (CNCR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.54%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):